Simulated fluctuations in plasma drug concentrations for patients receiving oxcarbazepine or carbamazepine extended-release capsules

Clinical Drug Investigation

Volumn 25, Issue 10, 2005, Pages 669-673

  Ahmad, Alaa ^a   Garnett, William R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 DIHYDRO 10 HYDROXYCARBAZEPINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DRUG METABOLITE; OXCARBAZEPINE; UNCLASSIFIED DRUG;

ARTICLE; COGNITIVE DEFECT; COMPUTER PROGRAM; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; EPILEPSY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; STEADY STATE;

EID: 24944494356     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525100-00006     Document Type: Article

References (29)

1. Loiseau P. Carbamazepine: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 262-72
2. Riva R, Albani F, Ambrosetto G, et al. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 1984; 25: 476-81
3. Hoppener RJ, Kuyer A, Meijer JW, et al. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980; 21: 341-50
4. Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol 1984; 41: 830-4
5. Aldenkamp AP, Alpherts WC, Moerland MC, et al. Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 1987; 28: 507-14
6. Jensen PK, Moller A, Gram L, et al. Pharmacokinetic comparison of two carbamazepine slow-release formulations. Acta Neurol Scand 1990; 82: 135-7
7. Macphee GJ, Butler E, Brodie MJ. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Epilepsia 1987; 28: 286-94
8. Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand 2004; 109: 374-7
9. Mirza WU, Rak IW, Thadani VM, et al. Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology 1998; 51: 1727-9
10. Hogan RE, Garnett WR, Thadani VM. Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: an open-label, 12- to 36-month continuation study. Clin Ther 2003; 25: 2586-96
11. Garnett WR, Levy B, McLean AM, et al. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia 1998; 39: 274-9
12. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42: 1023-42
13. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 1969-79
14. Sachdeo R, Beydoun A, Schachter S, et al. Safety and efficacy of oxcarbazepine monotherapy [abstract]. Neurology 1998; 50: A200
15. Sachdeo RC, Wasserstein A, Mesenbrink PJ, et al. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 2002; 51: 613-20
16. Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6
17. Spina E. Carbamazepine chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 236-46
18. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7
19. Shire US Inc. Carbatrol® (carbamazepine extended-release cap-sules) prescribing information. Wayne (PA): Shire US Inc., 2003
20. Novartis Pharmaceuticals Corporation. Trileptal® (ox-carbazepine) prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2004
21. Garnett WR, McLean AM, Zhang Y, et al. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules. Curr Med Res Opin 2003; 19: 519-25
22. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347-63
23. Volosov A, Xiaodong S, Perucca E, et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999; 66: 547-53
24. May TW, Rambeck B, Salke-Kellermann A. Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients. Acta Neurol Scand 1996; 93: 393-7
25. Edelbroek PM, Augustijn PB, de Haan GJ, et al. Change in oxcarbazepine (Trileptal) formulation is associated with more side effects and higher blood concentrations. J Neurol Neurosurg Psychiatry 2001; 71: 708-9
26. Kramer G. Oxcarbazepine: adverse effects. In: Levy RH, Matt-son RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 479-86
27. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 592-9
28. Bertilsson L, Hojer B, Tybring G, et al. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 1980; 27: 83-8
29. Eichelbaum M, Ekbom K, Bertilsson L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1975; 8: 337-41